Orchard Therapeutics (ORTX) Stock Rating Lowered by Zacks Investment Research

Orchard Therapeutics (NASDAQ:ORTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom. “

Separately, Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of Orchard Therapeutics in a research report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $23.40.

ORTX opened at $18.52 on Thursday. Orchard Therapeutics has a 1 year low of $8.65 and a 1 year high of $21.64.

A number of institutional investors have recently bought and sold shares of the business. FMR LLC acquired a new position in Orchard Therapeutics in the fourth quarter worth $321,012,000. RA Capital Management LLC acquired a new position in Orchard Therapeutics in the fourth quarter worth $76,227,000. Temasek Holdings Private Ltd acquired a new position in Orchard Therapeutics in the fourth quarter worth $15,730,000. Baillie Gifford & Co. acquired a new position in Orchard Therapeutics in the fourth quarter worth $14,550,000. Finally, ArrowMark Colorado Holdings LLC boosted its stake in Orchard Therapeutics by 10.9% in the first quarter. ArrowMark Colorado Holdings LLC now owns 712,591 shares of the company’s stock worth $12,741,000 after purchasing an additional 69,850 shares in the last quarter. 55.81% of the stock is currently owned by institutional investors.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

See Also: What kind of dividend yield to CEF’s pay?

Get a free copy of the Zacks research report on Orchard Therapeutics (ORTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.